Discontinued — last reported Q1 '22
Abbott Sales Rebates and Discounts increased by 160.3% to $682.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 160.3%, from $262.00M to $682.00M. Over 4 years (FY 2021 to FY 2025), Sales Rebates and Discounts shows an upward trend with a 17.0% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase may signal higher competitive pressure or a shift in sales mix toward high-volume, lower-margin channels.
This represents accrued liabilities for estimated rebates, volume discounts, and chargebacks owed to customers based on...
Highly relevant for pharmaceutical and medical device companies; peers often disclose this as a significant deduction from gross sales.
sales_rebates_and_discounts| Q4 '21 | Q4 '22 | Q4 '23 | Q4 '24 | Q4 '25 | |
|---|---|---|---|---|---|
| Value | $364.00M | $234.00M | $232.00M | $262.00M | $682.00M |
| QoQ Change | — | -35.7% | -0.9% | +12.9% | +160.3% |
| YoY Change | — | -35.7% | -0.9% | +12.9% | +160.3% |
We use cookies for analytics. See our Privacy and Cookie Policy.